ライフサイエンスコーパス: diagnostic test

1 nphysician labor, supplies, medications, and diagnostic tests).

2 c of diagnostic yield or global utility of a diagnostic test.

3 y multiple pathogens with a single DNA-based diagnostic test.

4 the absence of a biomarker or gold standard diagnostic test.

5 urther support the use of CI as an ancillary diagnostic test.

6 DTI proved to be a feasible and reproducible diagnostic test.

7 ous system lacking an adequate point-of-care diagnostic test.

8 eity has hindered development of a molecular diagnostic test.

9 as the initial tuberculous meningitis (TBM) diagnostic test.

10 ibody-negative by the serum anti-PLA2R ELISA diagnostic test.

11 loid beta positron emission tomography (PET) diagnostic tests.

12 aphy (8.0%) were the most commonly performed diagnostic tests.

13 abilities of current low-cost, point-of-care diagnostic tests.

14 ed by unknown sensitivity and specificity of diagnostic tests.

15 e of asymptomatic cases and little access to diagnostic tests.

16 ciated with false negatives when using Rapid Diagnostic Tests.

17 illustrated the need for rapid and accurate diagnostic tests.

18 ould deter the unsupervised use of multiplex diagnostic tests.

19 aria parasitaemia was identified using rapid diagnostic tests.

20 ator for the validation of new M. genitalium diagnostic tests.

21 demands the development of safe and accurate diagnostic tests.

22 f a composite validation strategy for ID-NGS diagnostic tests.

23 terpreting the results obtained by potential diagnostic tests.

24 tic gap due to the limited sensitivity of TB diagnostic tests.

25 form the basis for the future development of diagnostic tests.

26 ce at a site, and imperfect detection of the diagnostic tests.

27 aria parasitaemia was identified using rapid diagnostic tests.

28 are widely used in biochemical research and diagnostic tests.

29 a from whole blood is the first step in many diagnostic tests.

30 d the need for cost efficient and rapid ZIKV diagnostics tests.

31 educe erroneous and inconclusive findings in diagnostic testing.

32 mptomatic patients (n = 41,177) referred for diagnostic testing.

33 has created an unprecedented need for rapid diagnostic testing.

34 vely pathogenic variant is identified during diagnostic testing.

35 commonly asked by clinicians about COVID-19 diagnostic testing.

36 identifying exposed persons, and performing diagnostic testing.

37 he lack of convenient, timely, and sensitive diagnostic testing.

38 irical treatment; that is, treatment without diagnostic testing.

39 eshold at which they would recommend further diagnostic testing.

40 whom 7.4% had pulmonary embolism on initial diagnostic testing.

41 hese settings is difficult given the lack of diagnostic testing.

42 nd translating into high interpretability in diagnostic testing.

43 favorably with a commercial product used for diagnostic testing.

44 es were assessed: 1) enroll based on no LTBI diagnostic test; 2) enroll based on a positive tuberculi

45 of Diagnostic Accuracy Studies criteria for diagnostic test accuracy (DTA) studies, and the Cochrane

46 publication for imaging studies with higher diagnostic test accuracy (DTA), but it is unknown whethe

47 mortality, and harms; adherence to PrEP; and diagnostic test accuracy and discrimination.

48 rospective cohort studies, with 19 reporting diagnostic test accuracy data.

49 Purpose To evaluate the diagnostic test accuracy of dual-energy CT in helping de

50 The objective was to assess the diagnostic test accuracy of high-risk human papillomavir

51 for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) was follow

52 Diagnostic test accuracy was calculated per reader and f

53 Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy was used as a guideline for con

54 for a Systematic Review and Meta-Analysis of Diagnostic Test Accuracy, or PRISMA-DTA, guidelines, a s

55 With this approach, immunosensor-based diagnostic tests achieved 100% accuracy, suggesting that

56 cluding rates of medication prescription and diagnostic test administration, appeared to increase mor

57 from other conditions with minimal need for diagnostic testing after known or suspected population e

58 We provide an evidence-based diagnostic testing algorithm to enable appropriate clini

59 Implementation of a simple diagnostic testing algorithm to verify asthma diagnosis

60 w mNGS testing potentially fits into current diagnostic testing algorithms given data on mNGS test pe

61 lating hormone (TSH) measurement is the best diagnostic test; an elevated TSH level almost always sig

62 Rapid diagnostic test and quantitative PCR (qPCR) were used fo

63 n targeting resources, the prioritization of diagnostic testing and development of precision therapy.

64 , and blood samples were collected for rapid diagnostic testing and parasite transcription profiling.

65 RACD involved rapid diagnostic testing and treatment with artemether-lumefan

66 bovirus infection and sufficient samples for diagnostic testing and were included in the study.

67 In addition, the lack of specific diagnostic tests and biomarkers for Kawasaki disease mak

68 , time of arrival of the pandemic, number of diagnostic tests and criteria for testing, and national

69 ducing to $3.9 billion with lowest costs for diagnostic tests and drugs, including health-care saving

70 lead to long turnaround times for laboratory diagnostic tests and hamper epidemic control or patient

71 d to the development of noninvasive clinical diagnostic tests and has accelerated the evaluation of c

72 re Malaria has superior sensitivity to rapid diagnostic tests and microscopy in detecting asymptomati

73 ore the limitations of the current and novel diagnostic tests and the lack of evidence of therapeutic

74 rdiagnosis of uncomplicated malaria by rapid diagnostic tests and the potential for residual confound

75 recurrent pregnancy loss and evaluate novel diagnostic tests and treatments in adequately powered cl

76 enocarcinoma (the focus of CRC screening and diagnostic testing) and carcinoid tumors (which are clas

77 iral load decreases the sensitivities of HIV diagnostic tests, and further monitoring of the performa

78 ecently proposed SARS-CoV-2 sequencing based diagnostic tests, and is generally applicable to any dia

79 ding human spatial vision, interpretation of diagnostic tests, and the implementation of therapies fo

80 teractions, to develop accurate and portable diagnostic tests, and to advance the prevention and trea

81 nduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies.

82 There are limitations in current diagnostic testing approaches for Alzheimer disease (AD)

83 Many diagnostic tests are available that differentiate bacter

84 Few TB diagnostic tests are considered truly appropriate for po

85 Improved diagnostic tests are crucial to elimination of TF1-9 as

86 Rapid diagnostic tests are first-line assays for diagnosing in

87 Although diagnostic tests are fundamental to the ability to detec

88 accurate, and easily configurable molecular diagnostic tests are imperative to prevent global spread

89 However, diagnostic tests are lacking for many of these, includin

90 Accurate molecular diagnostic tests are necessary for confirming a diagnosi

91 neurodegeneration are unknown and antemortem diagnostic tests are not available, neuropathology studi

92 c regions, and sensitive point-of-care (POC) diagnostic tests are required to support this effort.

93 ripheral blood episignatures can be used for diagnostic testing as well as for the interpretation of

94 er incorporating dual HIV and syphilis rapid diagnostic tests as the first test in antenatal care to

95 Improved sensitivity and ease of diagnostic testing, as well as increased screening for e

96 des an exciting opportunity to develop rapid diagnostic tests at the point-of-care setting.

97 TBI should enroll based on the most specific diagnostic tests available (i.e., IGRAs) to avoid miscla

98 sitivity and specificity of the only two FFV diagnostic tests available-ELISA and qPCR-as well as the

99 anscription PCR to detect viral RNA or rapid diagnostic tests based on immunoassays to detect EBOV an

100 n test should be considered as an additional diagnostic test before performing time-consuming and pot

101 A focused physical evaluation and diagnostic testing can lack sensitivity and specificity.

102 Biosecurity measures and diagnostic testing can prevent further infections.

103 well as the need for ongoing improvement in diagnostic testing capabilities.

104 tories in their effort to achieve sufficient diagnostic testing capability for identifying infected i

105 gement of MSVD requires robust and sensitive diagnostic tests capable of rapid detection of MSV.

106 Participants were tested by rapid diagnostic tests (CareStart, Standard Diagnostics [SD] B

107 Diagnostic test characteristics, including positive and

108 Standard evaluations of diagnostic tests consist of estimating sensitivity, spec

109 A typical nucleic acid-based diagnostic test consists of three major steps: nucleic a

110 mpared to COVID(neg) patients at the time of diagnostic testing, COVID(pos) patients tended to have h

111 ould inform the development of point-of-care diagnostic tests designed to determine the specific anti

112 Diagnostic tests detecting HRP2 with limits of detection

113 as for recommendations spanning questions of diagnostic testing, determination of site of care, selec

114 apply the AWA methodology to evaluate a new diagnostic test developed in the Rapid Diagnostics in Ca

115 alth care, particularly in the area of rapid diagnostic test development and implementation.

116 Additionally, current diagnostic tests do not reliably distinguish between Mp

117 his Review, we summarize the crucial role of diagnostic tests during the first global wave of COVID-1

118 ing private providers to order definitive TB diagnostic tests earlier during patient consultation may

119 argeted sequencing panel as a cost-effective diagnostic test, especially in cancers such as acute leu

120 nant, consenting inpatient adults with rapid diagnostic test evidence of uncomplicated murine typhus

121 This approach could be developed as a novel diagnostic test for active Lyme borreliosis in patients

122 RT-RPA is a reliable diagnostic test for asymptomatic low-density infections.

123 The ECG remains the most widely used diagnostic test for characterization of cardiac structur

124 However, to date, there is no clinical diagnostic test for CMS subtyping.

125 rine (MSU) culture remains the gold standard diagnostic test for confirming urinary tract infection (

126 Yet, there is currently no adequate diagnostic test for early and rapid diagnosis of SAB.

127 Given there is no current 'gold standard' diagnostic test for FFV, efforts to elucidate the ecolog

128 udy of a nucleic acid amplification in vitro diagnostic test for Mycoplasma genitalium were analyzed

129 ers, 97 125 (5.3% of the total volume) had a diagnostic test for PE, including 25 870 patients who ha

130 ere we report the development of a molecular diagnostic test for SARS-CoV-2 based on an enhanced reco

131 n against the use of Xpert Ultra as a single diagnostic test for TBM; it cannot be used to "rule out"

132 ra assay appears to be a sensitive and rapid diagnostic test for the detection of MTBC DNA from tissu

133 anel (QIAstat-Dx RP) is a multiplex in vitro diagnostic test for the qualitative detection of 20 path

134 ful tools for the development of an accurate diagnostic test for this disease.

135 tion (PCR) testing of urine might serve as a diagnostic test for WD.

136 ant need for improved stewardship related to diagnostic testing for and treatment of IFIs.

137 may serve as a rapid, POC option for routine diagnostic testing for certain infectious diseases, incl

138 Diagnostic testing for chronic esophageal disorders reli

139 Accessibility of diagnostic testing for COVID-19 has been limited by inte

140 ncluded oral rehydration treatment and rapid diagnostic testing for malaria among under-5 children, a

141 The current review summarizes available diagnostic testing for neonatal disease, including discu

142 No recent data have investigated rates of diagnostic testing for pulmonary embolism (PE) in US eme

143 ethod for pandemic-scale automated molecular diagnostic testing for SARS-CoV-2.

144 for SARS-CoV-2 is an essential component of diagnostic testing for this virus, the majority of clini

145 ped and may be used to study the biology of, diagnostic testing for, and treatment of this neglected

146 Owing to the invasiveness of diagnostic tests for anaemia and the costs associated wi

147 tractive approach for developing blood-based diagnostic tests for both active and latent TB.

148 Currently available diagnostic tests for Clostridioides difficile infection

149 ere calculated for each enrolled patient and diagnostic tests for DED were performed at the screening

150 ormed and led to the ongoing use of enhanced diagnostic tests for detecting carbapenemases locally an

151 Point-of-care diagnostic tests for detecting SARS-CoV-2 antibodies: a

152 Diagnostic tests for fish allergy are hampered by the la

153 Diagnostic tests for foot-and-mouth disease (FMD) includ

154 There are several good diagnostic tests for Giardia infection.

155 we review the pathophysiology and available diagnostic tests for IDA in CKD, we discuss the literatu

156 Caution is recommended when choosing diagnostic tests for screening of asymptomatic children.

157 the need for commercially available specific diagnostic tests for TBRF spirochetes.

158 Current diagnostic tests for tuberculosis (TB) are not able to p

159 Diagnostic tests for tuberculosis (TB) usually require c

160 agnostics platform is applicable to numerous diagnostic test formats and diseases, and has the potent

161 controls were identified (without laboratory diagnostic testing) from three sites where Lyme disease

162 examination, advantages and disadvantages of diagnostic testing, guidance for individualized treatmen

163 R] $5,387-$8,430/QALY), depending on whether diagnostic testing had lasting or temporary effects on a

164 e (CAD) in symptomatic patients referred for diagnostic testing has declined, warranting optimization

165 Diagnostic testing has played and will continue to play

166 tly and no validated alternative preclinical diagnostic tests have been reported to date.

167 as causative of HCM and commonly included in diagnostic tests have limited or no evidence of disease

168 Owing to limitations of current diagnostic tests (i.e., poor sensitivity and delayed res

169 nning and echocardiography being the initial diagnostic tests if CTEPH is a concern.

170 regions is essential to proactively develop diagnostic tests, improve surveillance platforms to moni

171 cannot recommend the LAM-test as a valid BTB diagnostic test in cattle using either urine or milk.

172 sequencing can be performed as a first-tier diagnostic test in inpatient infants.

173 analysis should be implemented as a routine diagnostic test in meningioma and integrated into the WH

174 endelian DCM genes but have limited value in diagnostic testing in DCM at present.

175 House, a 2-day multidisciplinary workshop, "Diagnostic Testing in Older Adults with Cardiovascular D

176 gan production of VTM in-house in support of diagnostic testing in our hospital network.

177 low tests and hand-held analyzers facilitate diagnostic testing in resource limited settings and at t

178 The rollout of diagnostic testing in the United States was slow, leadin

179 Incorporating dual rapid diagnostic tests in antenatal care can be cost-saving ac

180 commendations in favor of or against various diagnostic tests in patients with suspected or known sar

181 the available evidence on the usefulness of diagnostic tests in such patients.

182 tically evaluate results from B. burgdorferi diagnostic tests in the context of the assay type and th

183 mple, design of behavioral and physiological diagnostic tests in the nascent field of computational p

184 nity to resolve a broad range of issues with diagnostic tests, including multiplexing, workflow simpl

185 uals with respiratory symptoms who underwent diagnostic testing, indicating that the human risk from

186 ality of life are developing new, more rapid diagnostic tests, investigating biomarkers associated wi

187 e 7: Reduction or avoidance of gluten before diagnostic testing is discouraged, as it may reduce the

188 erventions: health-care testing alone, where diagnostic testing is done only for individuals presenti

189 of nongonococcal urethritis (NGU), access to diagnostic testing is limited.

190 inical suspicion for COVID-19 when molecular diagnostic testing is negative and at least two weeks ha

191 Our recommendation for SARS-CoV-2 diagnostic testing is to select an assay with high sensi

192 r, the evidence for each of these additional diagnostic tests is limited.

193 h SP against intermittent screening by rapid diagnostic tests (ISTp).

194 In collaboration with an NHS diagnostic testing lab, we report the performance of the

195 g imaging and image-guided VAB into a single diagnostic test lowered the FNR to 6.2% (95% CI, 3.4%-10

196 were actively addressed by a large number of diagnostic test manufacturers.

197 al sensitivity of two most common SARS-CoV-2 diagnostic test modalities, polymerase chain reaction (P

198 In total, 150 intended diagnostic tests, mostly CT (n = 43, 29%) and bone scans

199 Malaria rapid diagnostic tests (mRDTs) that target histidine-rich prot

200 based on immunochromatographic malaria rapid diagnostic tests (mRDTs), which generally detect Plasmod

201 I) are challenging because of imperfect LTBI diagnostic tests.Objectives: To assess the effect on stu

202 e definition and limited access to sensitive diagnostic tests.Objectives: To estimate the prevalence

203 correct identification of each disease when diagnostic testing occurs either simultaneously or seque

204 red with TearLab osmometer, along with other diagnostic tests (Ocular Surface Disease Index questionn

205 Capsule endoscopy (CE) is the preferred diagnostic test of choice in the investigation of obscur

206 The UCNP-LF has potential for diagnostic testing of both symptomatic and asymptomatic

207 be identified with current non-tissue based diagnostic tests of prion disease.

208 In a few countries, the use of diagnostic testing on a massive scale has been a corners

209 articipants were screened with malaria rapid diagnostic tests once a month, whereas, in SST clusters,

210 Current diagnostic testing only partially predicts this clinical

211 Current diagnostic testing options include culture, molecular te

212 to food safety to the most frequent in vitro diagnostic tests, partially conducted in automated sampl

213 eptual framework for understanding molecular diagnostic test performance, discuss the nuance of test

214 obacterial testing are important for optimal diagnostic test performance.

215 Diagnostic tests performed included 1,000 (1-3)-beta-d-g

216 Continuous global improvement in diagnostic test preparedness is essential for more rapid

217 Available rapid malaria diagnostic tests present limitations in analytical sensi

218 Exploratory study of a diagnostic test, prospective, case and control design.

219 Parasite prevalence by rapid diagnostic test (RDT) declined from 9.1% (95% confidence

220 inimum = 2, maximum = 7) by microscopy/rapid diagnostic test (RDT) from 57 DHSs conducted between Nov

221 cholerae (n = 78/849), the odds that a rapid diagnostic test (RDT) or qPCR was positive was reduced b

222 red malaria infection by microscopy or rapid diagnostic test (RDT), diarrhoea, acute respiratory infe

223 positive O. tsutsugamushi or R. typhi rapid diagnostic test (RDT), serology, or PCR.

224 ion was compared to a WHO-prequalified rapid diagnostic test (RDT).

225 Rapid diagnostic testing (RDT) can facilitate earlier optimiza

226 ion (LAMP) was compared to traditional rapid diagnostic testing (RDT) for the improved detection of i

227 mic countries are heavily reliant upon rapid diagnostic tests (RDT) for malaria case identification a

228 bine performance estimates of standard rapid diagnostic tests (RDT) from trials of intermittent scree

229 Microscopy and rapid diagnostic tests (RDTs) are the main diagnostic tools fo

230 The use of malaria rapid diagnostic tests (RDTs) as a source for nucleic acids th

231 investigating suspected false-negative rapid diagnostic tests (RDTs) due to pfhrp2/3 deletions.

232 The use of rapid diagnostic tests (RDTs) for blood cultures has become st

233 Rapid diagnostic tests (RDTs) for bloodstream infections (BSIs

234 r guidelines and algorithms, available rapid diagnostic tests (RDTs) for common acute undifferentiate

235 spective study assessed performance of rapid diagnostic tests (RDTs) for detection of HCV antibodies.

236 te areas of malaria-endemic countries, rapid diagnostic tests (RDTs) have dramatically improved paras

237 histidine-rich protein 2 (HRP2)-based rapid diagnostic tests (RDTs) identifying Plasmodium falciparu

238 Rapid diagnostic tests (RDTs) that detect the Plasmodium falci

239 or lysate antigens and novel IgG1 rK39 rapid diagnostic tests (RDTs) were assessed with Indian VL ser

240 s' inclination to delay ordering of accurate diagnostic tests relevant to TB.

241 The sensitivity of current gold-standard diagnostic tests relies upon antibody formation, which i

242 Diagnostic testing remained one of the limiting factors

243 ull appreciation of the clinical impact of a diagnostic test requires analyses that integrate sensiti

244 spected COVID-19 cases that yielded negative diagnostic test results (ie, suspected false-negative te

245 infection and/or recovery times, or disease diagnostic test results.

246 data, as well as self-reported symptoms and diagnostic testing results, from individuals in the Unit

247 such as avoidance of the use of unnecessary diagnostic tests, risk factors for severe disease, indic

248 first antenatal care visit with a dual rapid diagnostic test (scenario one).

249 during late antenatal care with a dual rapid diagnostic test (scenario three) was cost-effective comp

250 Adjunctive diagnostic testing should be considered to detect potent

251 Routine infant diagnostic testing should ideally distinguish vaccine fr

252 ic for CIDP, meaning that the results of the diagnostic tests should be carefully interpreted.

253 These questions relate to when diagnostic tests should be completed, which diagnostic t

254 studies with highly sensitive malaria rapid diagnostic tests should be considered.

255 portant unmet research needs in the COVID-19 diagnostic testing space.

256 criteria can be supplemented with additional diagnostic tests such as CSF examination, MRI, nerve bio

257 osing CIDP and the value of newly introduced diagnostic tests such as nerve ultrasound and testing fo

258 Diagnostic tests such as sensitivity (SN), specificity (

259 and showed better agreement with additional diagnostic testing than triple-rule-out CT angiography.

260 (Pan-Lassa RDT) is a point-of-care, in vitro diagnostic test that utilizes a mixture of polyclonal an

261 tection methods to enable the development of diagnostic tests that are well suited for resource-limit

262 However, more precise diagnostic tests that can assess biologic tumor features

263 ion has been impeded by the lack of reliable diagnostic tests that can identify animals early in the

264 opment of rapid and affordable point-of-care diagnostic tests that can simultaneously detect AMR, nov

265 boratories transition to culture-independent diagnostic tests that detect EAEC.

266 ndings identified evidence-based targets for diagnostic tests that distinguish between latent and act

267 As a functional diagnostic test, this parameter reached a sensitivity of

268 A prototype lateral flow rapid diagnostic test to detect IgG4 to both Ov-16 and OVOC326

269 ent of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immu

270 Detraining is a commonly used diagnostic test to identify physiological hypertrophy, w

271 A rapid and early diagnostic test to identify the encephalopathic babies a

272 s ready-to-use platform can be tailored as a diagnostic test to meet the requirements for point-of-ca

273 has created an unprecedented need for rapid diagnostic testing to enable the efficient treatment and

274 Diagnostic testing to identify persons infected with sev

275 tilize, and the utility (or lack thereof) of diagnostic testing to predict the severity of a future a

276 need for sensitive, specific, and affordable diagnostic tests to identify infected individuals, not a

277 Advances in rapid diagnostic tests to improve the detection of carbapenem

278 ne for evaluating male infertility, advanced diagnostic tests to investigate sperm quality and functi

279 Currently, there are no routine diagnostic tests to noninvasively map PCr distribution w

280 lised residual material from Abbott m2000 Ct diagnostic tests to sequence 99 ocular Ct samples from A

281 diagnostic tests should be completed, which diagnostic tests to utilize, and the utility (or lack th

282 document addresses new information regarding diagnostic testing, treatment and chemoprophylaxis with

283 trained lay worker with a blood-based rapid diagnostic test (used in facility-based testing), or by

284 ei-infected cases to develop a real-time PCR diagnostic test using two differentially expressed genes

285 come widely known, many laboratories perform diagnostic tests using methods such as RT-PCR or reverse

286 A PCR-based diagnostic test was developed and confirmed fully penetr

287 A diagnostic test was used to calculate the sensitivity, s

288 aphy (>= 50%), as well as downstream cardiac diagnostic testing, was investigated.

289 Using this new diagnostic test, we aimed to identify clinical and labor

290 For the dichotomous diagnostic test, we selected 60 study participants (23-9

291 of AGE symptom onset for clinician-requested diagnostic testing were tested for norovirus, and positi

292 lidation, verification and implementation of diagnostic tests were actively addressed by a large numb

293 Recommendations for or against various diagnostic tests were formulated and graded after the ex

294 during which at least 10% of RSV and/or flu diagnostic tests were positive.

295 ive workflow could be applicable for routine diagnostic testing where quantitative results are essent

296 uated for tuberculosis (TB), a lack of rapid diagnostic tests which can fully describe TB resistance

297 To supplement conventional diagnostic testing, which is constrained by capacity, co

298 Infants of seropositive mothers underwent diagnostic testing with quantitative polymerase chain re

299 We quantitatively assessed the accuracy of diagnostic tests with bivariate random-effects meta-anal

300 An ideal diagnostic test would identify all possible infectious c